3',5'-Cyclic-GMP Phosphodiesterases
"3',5'-Cyclic-GMP Phosphodiesterases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate.
Descriptor ID |
D015106
|
MeSH Number(s) |
D08.811.277.352.640.155 D12.644.360.009 D12.776.476.009
|
Concept/Terms |
3',5'-Cyclic-GMP Phosphodiesterases- 3',5'-Cyclic-GMP Phosphodiesterases
- 3',5' Cyclic GMP Phosphodiesterases
- Phosphodiesterases, 3',5'-Cyclic-GMP
- 3,5-Cyclic GMP Phosphodiesterase
- 3,5 Cyclic GMP Phosphodiesterase
- GMP Phosphodiesterase, 3,5-Cyclic
- Phosphodiesterase, 3,5-Cyclic GMP
- 3',5'-Cyclic-GMP Phosphodiesterase
- 3',5' Cyclic GMP Phosphodiesterase
- Phosphodiesterase, 3',5'-Cyclic-GMP
- 3,5-Cyclic GMP 5-Nucleotidohydrolase
- 3,5 Cyclic GMP 5 Nucleotidohydrolase
- 5-Nucleotidohydrolase, 3,5-Cyclic GMP
- GMP 5-Nucleotidohydrolase, 3,5-Cyclic
- 3',5'-Cyclic GMP 5'-Nucleotidohydrolase
- 3',5' Cyclic GMP 5' Nucleotidohydrolase
- 5'-Nucleotidohydrolase, 3',5'-Cyclic GMP
- GMP 5'-Nucleotidohydrolase, 3',5'-Cyclic
- 3',5'-Cyclic GMP Phosphodiesterase
- GMP Phosphodiesterase, 3',5'-Cyclic
- Phosphodiesterase, 3',5'-Cyclic GMP
|
Below are MeSH descriptors whose meaning is more general than "3',5'-Cyclic-GMP Phosphodiesterases".
Below are MeSH descriptors whose meaning is more specific than "3',5'-Cyclic-GMP Phosphodiesterases".
This graph shows the total number of publications written about "3',5'-Cyclic-GMP Phosphodiesterases" by people in this website by year, and whether "3',5'-Cyclic-GMP Phosphodiesterases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 | 2003 | 0 | 1 | 1 | 2005 | 0 | 2 | 2 | 2007 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "3',5'-Cyclic-GMP Phosphodiesterases" by people in Profiles.
-
Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007 Jul 17; 116(3):238-48.
-
Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol. 2005 Nov 01; 96(9):1334-6.
-
Levine LA, Greenfield JM, Estrada CR. Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med. 2005 Mar; 2(2):241-7.
-
Archer SL, Gragasin FS, Webster L, Bochinski D, Michelakis ED. Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. Drugs Aging. 2005; 22(10):823-44.
-
Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003 Oct 28; 108(17):2066-9.
-
Thébaud B, Michelakis E, Wu XC, Harry G, Hashimoto K, Archer SL. Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. Pediatr Res. 2002 Jul; 52(1):19-24.
-
Tur-Kaspa I, Segal S, Moffa F, Massobrio M, Meltzer S. Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies. Hum Reprod. 1999 Jul; 14(7):1783-4.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|